These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19539908)

  • 1. High dose cabergoline in management of ovarian hyperstimulation syndrome.
    Ata B; Seyhan A; Orhaner S; Urman B
    Fertil Steril; 2009 Sep; 92(3):1168.e1-1168.e4. PubMed ID: 19539908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Carizza C; Abdelmassih V; Abdelmassih S; Ravizzini P; Salgueiro L; Salgueiro PT; Jine LT; Nagy P; Abdelmassih R
    Reprod Biomed Online; 2008 Dec; 17(6):751-5. PubMed ID: 19079957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
    Shaltout A; Shohyab A; Youssef MA
    Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):254-8. PubMed ID: 22948132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Esinler I; Bozdag G; Karakocsokmensuer L
    Arch Gynecol Obstet; 2013 Nov; 288(5):1159-63. PubMed ID: 23677417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
    Rollene NL; Amols MH; Hudson SBA; Coddington CC
    Fertil Steril; 2009 Sep; 92(3):1169.e15-1169.e17. PubMed ID: 19608177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
    Leitao VM; Moroni RM; Seko LM; Nastri CO; Martins WP
    Fertil Steril; 2014 Mar; 101(3):664-75. PubMed ID: 24360566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
    Kasum M; Vrčić H; Stanić P; Ježek D; Orešković S; Beketić-Orešković L; Pekez M
    Gynecol Endocrinol; 2014; 30(12):845-9. PubMed ID: 25093428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis.
    Youssef MA; van Wely M; Hassan MA; Al-Inany HG; Mochtar M; Khattab S; van der Veen F
    Hum Reprod Update; 2010; 16(5):459-66. PubMed ID: 20354100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial.
    Seow KM; Lin YH; Bai CH; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Hwang JL
    Reprod Biomed Online; 2013 Jun; 26(6):562-8. PubMed ID: 23608246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
    Garcia-Velasco JA
    Reprod Biomed Online; 2009; 18 Suppl 2():71-5. PubMed ID: 19406035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
    Kozovski G; Angelova M; Kacarova P
    Akush Ginekol (Sofiia); 2014; 53(5):34-5. PubMed ID: 25558669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
    Gaafar S; El-Gezary D; El Maghraby HA
    Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome.
    Turktekin N; Karakus C; Ozyurt R
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1248-1254. PubMed ID: 35253181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
    Kalampokas T; Creatsas G; Kalampokas E
    Gynecol Endocrinol; 2013 Feb; 29(2):98-100. PubMed ID: 23110560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
    Tehraninejad ES; Hafezi M; Arabipoor A; Aziminekoo E; Chehrazi M; Bahmanabadi A
    J Assist Reprod Genet; 2012 Mar; 29(3):259-64. PubMed ID: 22231013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.